Paraneoplastic Syndromes Clinical Trial
Official title:
Killer T Cell Activity in the Paraneoplastic Neurologic Syndromes
NCT number | NCT00327236 |
Other study ID # | RDA-0148 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | January 1995 |
Est. completion date | February 2018 |
Verified date | April 2019 |
Source | Rockefeller University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The investigators believe that T cells, cells that are a part of the immune system, are what are causing the neurological problems while also attacking tumor cells. This protocol studies the clinical status of patients with paraneoplastic neurological disorder (PND) as well as their blood to understand the relationship between their neurological disease, their cancer, and their immune system.
Status | Completed |
Enrollment | 109 |
Est. completion date | February 2018 |
Est. primary completion date | February 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Year and older |
Eligibility |
Inclusion Criteria: - Neurological disease which is suspected to be paraneoplastic - No known active additional malignancy other than non-melanoma skin cancer Exclusion Criteria: - Known central nervous system (CNS) metastasis - Known active additional malignancy - No pulmonary disease which limits daily activities if leukapheresis: must be 14 or older no known hepatitis B or C, HIV, or syphilis (by history or prior negative tests) no known IV drug users HgB > 8.5 WBC > 3,500 platelets > 100,000 INR < 2 if large blood draw (1/2 to 1 unit; children 3 ml/kg) in lieu of leukapheresis: no known IV drug users HgB > 10 WBC > 3,500 platelets > 100,000 INR < 2 if lumbar puncture: platelets > 120,000 INR < 1.2 must be 14 or older |
Country | Name | City | State |
---|---|---|---|
United States | Rockefeller University Hospital | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Rockefeller University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Immunologic responses to tumor antigens in vitro | ELISPOT | throughout study |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05645185 -
Characterisation of Clinical Phenotypes and Outcomes of Ma2 Patient
|
||
Completed |
NCT04653571 -
CASPR2 Encephalitis Initial Symptoms
|
||
Active, not recruiting |
NCT03963700 -
Tumor Characteristics in Patients With Paraneoplastic Neurological Syndromes (PNS)
|
||
Completed |
NCT00378326 -
Immunotherapy of the Paraneoplastic Syndromes
|
N/A | |
Completed |
NCT05942872 -
CICLOPS Immune Checkpoint Inhibitors Neurotoxicity: Long-term Outcomes, Predictors, and Survival.
|